Let's Get Started

Food&Health

Rockwell Medical RMTI Breakout Alert

Rockwell Medical RMTI Breakout Alert

Jan 13, 2022

Rockwell Medical RMTI is up 59% after due to a massive amount of volume being injected into this little well known stock that has been crashing for the last twelve months. I have written a full report on RMTI that you can read below.

However, before you read this insightful information, sign up below, let’s stay in contact.

LVGI

Limitless Venture Group announced today, “ Announced that its partner in South Korea, Jeil Pharmaceutical” However, before we get started, let’s review some basic information on this company.

Rockwell RMTI Company Summary

Company Name:  Rockwell Medical , Inc

Ticker: RMTI

Exchange: NASDAQ

Website: www.RockwellMed.com.

Rockwell Company Summary

Rockwell Medical RMTI is a commercial-stage biopharmaceutical company developing and commercializing its next-generation parenteral iron technology platform. The iron technology is Ferric Pyrophosphate Citrate. It has the potential to lead transformative treatments for iron deficiency in multiple disease states, reduce healthcare costs and improve patients’ lives.

The Company has two FDA-approved therapies indicated for patients undergoing hemodialysis. These are the first two products developed from the FPC platform. Rockwell Medical is also advancing its FPC platform by developing FPC for the treatment of iron deficiency anemia in patients outside of dialysis. These patients are receiving intravenous medications in the home infusion setting.

In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States.

RMTI News

Jan. 13, 2022

Announced that its partner in South Korea, Jeil Pharmaceutical Co., Ltd. (“Jeil”), has received regulatory approval by the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea for Triferic Injection.

Also, Triferic Injection (ferric pyrophosphate citrate sodium sulfate co-precipitate hydrate injection) marketed in the United States as Triferic AVNU (ferric pyrophosphate citrate injection) for iron supplementation therapy. Hence, it creates hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. HERE

Rockwell Medical 1 Month Chart

RMTI

RMTI 1 Day Chart

RMTI

Rockwell Technical Analysis

The news was incredible that RMTI Announced that its partner in South Korea, Jeil Pharmaceutical Co , has received regulatory approval by the Ministry of Food and Drug Safety of the Republic of Korea for Triferic Injection.

Also, The real question is, what is it going to do now? Well, it has pulled back as expected but it will now consolidate then make a move up or down depending on the indicators within the consolidation. It is too early to determine which way it will move, but it is showing an early tendency to go bullish.

Hence, The stock responded with a massive amount of volume and a PPS increase of 59%. RMTI skyrocketed from $.40 to $.65 with 50 million+ shares traded.

I would expect RMTI to go up with the news today. It was huge and the stock responded with a massive amount of volume and a PPS increase of 251%. LVGI skyrocketed from $.011 to $.0388 with 50 million+ shares traded.

I am thinking RMTI will continue to go down as it has for over a year but there is opportunities with quick scalps. Stay tuned traders

Moreover, Remember, to never try and catch a falling safe, or a knife for that matter. Simply let it fall to the ground, walk over, and pick up the money. If you enjoyed this article, sign up below, I promise I will never spam you. Also, I’m pretty darn good at picking winners. Let’s make some trades together!

LVGI

read more
Limitless Venture Group LVGI Bullish?

Limitless Venture Group LVGI Bullish?

Jan 11, 2022

Limitless Venture Group LVGI is up 98% after due to a massive amount of volume being injected into this little well known stock that has been crashing for the last 6 months. I have written a full report on LVGI that you can read below.

However, before you read this insightful information, sign up below, let’s stay in contact.

LVGI

Limitless Venture Group announced today, “the best revenue year in the history of LVGI and update shareholders on what’s ahead for 2022 and beyond.” However, before we get started, let’s review some basic information on this company.

Limitless Venture Group LVGI Company Summary

Company Name:  Limitless Venture Group, Inc

Ticker: LVGI

Exchange: OTC

Website: www.lvginc.com

Limitless Venture Group, Inc. Company Summary

Limitless Venture Group provides its shareholders with access to leading small and medium-sized businesses focused on growth. Leveraging its permanent capital base, disciplined long-term approach, and actionable expertise, LVGI owns controlling interests in its subsidiaries as it partners with management teams to build businesses with the capacity to unlock significant value for its shareholders.

The Company currently has three primary subsidiaries: Rokin, Inc., KetoSports, Inc. and Jasper Benefit Solutions, LLC.

Also, Rokin was founded in 2016 with a mission to provide our customers with the highest quality, technology-driven vaping products available while providing exceptional customer service.

Moreover, KetoSports products flush the body with ketones, raising blood ketone levels within a few minutes.

Also, Jasper Benefit Solutions, LLC (JBS), founded in 2018 with headquarters just outside Nashville, TN, is a Managing General Underwriter (MGU) specializing in risk management services for small to medium self-funded employer “Groups”. 

Consequently, Rokin, KetoSports & Jasper Benefit Solutions have benefitted greatly from the management expertise at LVG.

LVGI News

January 11 , 2022

Announced the best revenue year in the history of LVGI and update shareholders on what’s ahead for 2022 and beyond. HERE

December 7, 2021

Announced that it has signed an LOI to acquire 100% of an Oklahoma operating grow facility with both Indoor and outdoor operations, exclusive to LVGI for 60 days from the signing of the LOI. HERE

Limitless 1 Month Chart

LVGI

LVGI 1 Day Chart

LVGI

Limitless Venture Group Technical Analysis

The news was incredible that Limitless Venture Group LVGI released today was huge and the stock responded with a massive amount of volume and a PPS increase of 251%. LVGI skyrocketed from $.011 to $.0388 with 50 million+ shares traded.

The real question is, what is it going to do now? Well, it has pulled back as expected but it will now consolidate. Next, it will make a move up or down depending on the indicators within the consolidation. It is too early to determine which way it will move, but it is showing an early tendency to bearish.

I would expect The news was incredible that Limitless Venture Group LVGI released today was huge. The stock responded with a massive amount of volume and a PPS increase of 251%. LVGI skyrocketed from $.011 to $.0388 with 50 million+ shares traded.

I would expect, the news was incredible that Limitless Venture Group LVGI released today was huge and the stock responded. Therefore, LVGI opened with a massive amount of volume and a PPS increase of 251%. LVGI skyrocketed from $.011 to $.0388 with 50 million+ shares traded.

I am thinking Limitless will continue to drop in PPS until it fully consolidates then it will make a run! Stay tuned traders

Remember, to never try and catch a falling safe, or a knife for that matter. Simply let it fall to the ground, walk over, and pick up the money and walk away. If you enjoyed this article, sign up below, I promise I will never spam you and I’m pretty darn good at picking winners. Let’s make some trades together!

LVGI

read more
TDH Holdings PETZ ready to bounce?

TDH Holdings PETZ ready to bounce?

Jan 11, 2022

TDH Holdings PETZ has been bearish for almost a month and I believe it is almost ready to reverse it’s trend, stay tuned! To review TDH Holdings, keep on reading, there is some good stuff below that you don’t want to miss.

TDH Holdings PETZ Company Summary

Company Name: TDH Holdings, Inc.

Ticker: PETZ

Exchange: NASDAQ

Website: www.tiandihui.com

TDH Holdings Company Summary:

Founded in April 2002, TDH Holdings, Inc. (the “Company”) (NASDAQ: PETZ), is a developer, manufacturer and distributer of a variety of pet food products under multiple brands that are sold in China, Asia and Europe. More information about the Company can be found at 

What was the last news for PETZ?

Dec. 10, 2021 

TDH Holdings PETZ announced today its financial results for the six months ended June 30, 2021.

Revenues decreased by 52.46% to $0.13 million for the first half of 2020. Eesh, that is bad news bears! I am confident that is

PETZ 1 Month Chart

PETZ 1 Day Chart

PETZ

PETZ Technical Analysis

TDH Holdings PETZ $4.00 to $.60 is an incredible drop, 80% to be exact. As a trader we should be waiting the bottom because it should be coming here soon.

In fact, it tapped over $.711 which was it’s first resistance point. Currently, it attempting to breakthrough. Stay tuned because I am leery this a head fake unless it can beat $.78. Put it on your watchlist but be careful for that double confirmation.

read more
Petros Pharmaceuticals PTPI short squeeze

Petros Pharmaceuticals PTPI short squeeze

Jan 7, 2022

Petros Pharmaceuticals PTPI is possibly about to explode again as the short position increases as PPS is ticking up. Pay attention to PTPI as this stock may skyrocket

Petros PTPI company summary

Company Name: Petros Pharmaceuticals, Inc. 

Ticker: (PTPI)

Exchange: NASDAQ

Short Squeeze Article: HERE

Petros PTPI Company Summary:

Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men’s health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health issues, including, but not limited to, erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie’s disease, hormone health, and substance use disorders.

Why is it red HOT?

The NEWS:

Petros  reported positive over-the-counter (OTC) draft label comprehension study results for its erectile dysfunction (ED) Drug STENDRA® (avanafil). This Pivotal Label Comprehension Study was designed to assess comprehension of a draft STENDRA® Drug Facts Label intended for OTC use. 

What did the say, “The label comprehension study is a key component of our plans to help expand access for STENDRA beyond the prescription model, and to make 
The first “potentially the first prescription-grade ED medication to become available over-the-counter in the United States.” EVER?!?

The Short Squeeze

Look HERE at our buddies over at Fintel.io. This stock has a big short position and could go crazy!

PTPI 5 Day Chart

PTPI 5 Day Analysis

The convergence point is coming Traders! All signs are pointing to a short squeeze! It is coming late Friday or Monday! Once PTPI breaks $2.82 & $2.90, boom like a rocket ship!

PTPI 1 Day Chart

1 Day Analysis

You can clearly see the $2.82 resistance. Get ready traders because I’ve been following PTPI for a while and I can hear the juice machine warming up for the BIG squeeze.

read more
Freeline Therapeutics FRLN report

Freeline Therapeutics FRLN report

Jan 6, 2022

Freeline Therapeutics Holdings plc (FRLN) is going down down down but is the there a reversal coming soon?

Freeline Therapeutics FRLN Company Summary

Company Name: Freeline Therapeutics Holdings plc

Ticker: FRLN

Exchange: NASDAQ

Website: https://www.freeline.life/

Freeline Therapeutics FRLN Company Summary

Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated systemic gene therapies. The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases.

Freeline uses its proprietary, rationally designed AAV vector, along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into the patient’s bloodstream.

The Company’s integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing, and commercialization. The Company has clinical programs in hemophilia B, Fabry disease, and Gaucher disease Type 1. Freeline is headquartered in the UK and has operations in Germany and the US.

Freeline Therapeutics FRLN News

Jan. 06, 2022

Announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for FLT201 as an investigational gene therapy for the treatment of Gaucher disease Type 1.

“The FDA clearance of this IND is an important milestone for FLT201, which is the first AAV-mediated gene therapy for patients with Gaucher disease Type 1 in the clinic,” said Michael Parini, Chief Executive Officer of Freeline. “Our FLT201 program harnesses our unique scientific platform capabilities – our highly potent, proprietary AAVS3 capsid, robust CMC and pre-clinical data across all our programs, and our advanced protein engineering capabilities – to develop a potentially transformative treatment for patients suffering from Gaucher disease. The entry of our third program into the clinic is important validation of the advantage of Freeline’s portfolio approach to development.”

Freeline Therapeutics FRLN Stock Chart

FRLN Analysis

There is resistance at $2.10 and $2.15 and this stock will continue to go down unless it can correct and breakout of the two resistance points. The news is great, so I expect a consolidation soon and a correction. Make sure to keep this on your radar.

read more
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) announces 2b clinical trials!

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) announces 2b clinical trials!

Dec 14, 2021

Company Name: BELLUS Health Inc. 

Ticker: (BLU)

Exchange: NASDAQ

Website:  www.bellushealth.com

Company Summary:

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RCC and other hypersensitization-related disorders. The Company’s product candidate, BLU-5937, has successfully completed a Phase 2b trial in RCC and is planning a Phase 3 program that is expected to begin in 2022.

Why did it go up almost 100%?

Link HERE – LAVAL, Quebec, December 13, 2021–(BUSINESS WIRE)–BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that the 50 mg and 200 mg BID doses of BLU-5937 in its Phase 2b SOOTHE trial for the treatment of RCC achieved statistical significance on the primary endpoint with 34% placebo-adjusted reduction in 24-hour cough frequency observed (p ≤ 0.005) at day 28. BLU-5937 was generally well-tolerated, with low rates of taste-related adverse events reported (≤6.5%) at all doses.

Mr. Roberto Bellini, Chief Executive Officer of BELLUS Health commented, “We are extremely pleased with the compelling topline results from the Phase 2b SOOTHE trial which highlight BLU-5937’s best-in-class potential for the treatment of refractory chronic cough. RCC is a prevalent and growing condition that significantly impacts the quality of life of an estimated 9 million patients in the United States and 9 million patients in Europe.”

5 Day Technical Analysis:

There are a lot of traders at $9.05, so if this stock can beat $9.05 tomorrow, I like it. If not, and I’m thinking it won’t, stay away. Caveat, the news is really good, so I hold out hope, but I don’t like the huge 70% gap up. Happy trading and always play it safe with trailing stops!

read more
Biofrontera Inc. (Nasdaq: BFRI Patent allowed!

Biofrontera Inc. (Nasdaq: BFRI Patent allowed!

Dec 14, 2021

Company Name: Biofrontera Inc. 

Ticker: (BFRI)

Exchange: NASDAQ

Website: www.biofrontera-us.com

Company Summary: 

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.

Why did it go up over 100%?

WOBURN, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Biofrontera Pharma GmbH’s U.S. patent number 17/215,785 (‘785 patent), titled “Illumination device for photodynamic therapy, method for treating a skin disease and method for operating an illumination device,” which protects a number of innovations relating to the RhodoLED XL lamp.

WOBURN, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the first subject has been enrolled in the Phase 2b study performed by Biofrontera Bioscience GmbH to evaluate the safety and efficacy of Ameluz® in combination with the red-light lamp BF-RhodoLED® for the treatment of moderate-to-severe acne with photodynamic therapy (Ameluz®-PDT).

5 Day Chart Technical Analysis

I like the stock! Great news and the 5 day is bullish and has solid news with a patent being accepted and a phase 2b clinical trial being announced. 

1 Day Chart Technical Analysis

Technical Analysis:

I like the stock only IF the bearish trend continues in the morning, stay AWAY until there is consolidation and a double confirmation of a bullish move. 

read more
Petros Pharma (PTPI) to launch an OTC Erectile dysfunction pill?

Petros Pharma (PTPI) to launch an OTC Erectile dysfunction pill?

Dec 14, 2021

Company Name: Petros Pharmaceuticals, Inc. 

Ticker: (PTPI)

Exchange: NASDAQ

Website: https://STENDRA.com/.

Company Summary:

Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men’s health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health issues, including, but not limited to, erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie’s disease, hormone health, and substance use disorders.

Why did it go up over 100%?

Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, today reports positive over-the-counter (OTC) draft label comprehension study results for its erectile dysfunction (ED) Drug STENDRA® (avanafil). This Pivotal Label Comprehension Study was designed to assess comprehension of a draft STENDRA® Drug Facts Label intended for OTC use. This study is a key component in the Company’s plans to engage in discussions with the FDA to expand the product’s access through application for a possible OTC pathway. Early study indicators show positive label comprehension outcomes in the study, which has encouraged the Company to initiate the next step, a Self-Selection Study, as it continues to build the case for the FDA for OTC access to STENDRA.

“The label comprehension study is a key component of our plans to help expand access for STENDRA beyond the prescription model, and to make STENDRA potentially the first prescription-grade ED medication to become available over-the-counter in the United States. While the process of gathering data to be shared with the U.S. Food and Drug Administration (FDA) continues, we are enthusiastic about our progress toward providing new hope for the millions of men suffering from this condition,” commented Fady Boctor, Petros’s President and Chief Commercial Officer.

The first “potentially the first prescription-grade ED medication to become available over-the-counter in the United States.” EVER?!?

I’m a big fan of this company and the recent news it released. Let’s take a look at the chart.

5 Day Technical Analysis:

It’s been gapping up and pulling back for the last 4 days and it looks like it is still bullish but it is possibly about to go bearish! Let’s tak a close look at the 1 day.

1 Day CHart Technical Analysis

It’s very simple, can it beat $4.38? Yes, then I would wait for a pull back and then swing trade it for a quick scalp. If it can’t, I would expect a pullback then consolidation and then a run! Overall, I love the stock because of the news. The first OTC ED med, say what!?!?

read more
BLTSW and QLGN Consolidate After Explosive Runs

BLTSW and QLGN Consolidate After Explosive Runs

Nov 24, 2021

Company Snapshot

Company Name: Bright Lights Acquisition Corp.

Ticker: BLTSW

Exchange: NASDAQ

Website: https://www.brightlightsacquisition.com/

Company Summary:

Bright Lights is a blank check company that was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Bright Light’s efforts to identify a prospective target business are not limited to a particular industry or geographic region, but Bright Lights intends to focus on businesses operating in the consumer products and media, entertainment and sports sectors. t 

Why did it go up over 100%?

MANSCAPED, a leader and pioneer in men’s grooming, has entered into a definitive business combination agreement with Bright Lights Acquisition Corp.

What does MANSCAPED do?

Founded by Paul Tran in 2016, San Diego, California-based MANSCAPED™ is the leading men’s lifestyle consumer brand and male grooming category creator trusted by over four million men worldwide. The product range includes a diversified line of premium tools, formulations, and accessories that are intelligently designed to introduce a whole new self-care routine for men.

5 Day Chart

Technical Overview

We like it! It jumped over 30% on acquisition news and had a moderate retrace and showed bullish tendency by midday and after market trading was very bullish reaching a new high. Be very careful in premarket buying, if it is crazy action we advise you to wait for a sell off at the bell and then make a decision on the trade based on a new pull back low in regards to the previous lows of Tuesday. As long as the lows are continuously higher than the last lows, this appears to be a stable play. 

Company Snapshot

Company Name: Qualigen Therapeutics, Inc. 

Ticker: QLGN

Exchange: NASDAQ

Website: https://www.qualigeninc.com/

Company Summary:

Qualigen is a biotechnology company focused on the development of novel therapeutic products for the treatment adult and pediatric patients with rare cancers, as well as expansion of its flagship FastPack® diagnostic platform. 

Why did it go up over 100%?

On November 15, 2021, Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced financial results for the third quarter of 2021. The company reported $1.2 million in revenues for the third quarter of 2021, compared to $0.8 million for the three months ending September 30, 2020. The increase was primarily due to a recovery from the effects of the COVID-19 pandemic. The cost of product sales in the third quarter of 2021 were $1.0 million, or 86% of net product sales, compared to $0.9 million, or 110% of net product sales, for the three months ending September 30, 2020. The increase was primarily due to higher unit volumes of product sales, and the improvement in gross margin percentage was due primarily to economies of scale.

5 Day Chart

Technical Analysis

We have seen a strong bullish tendency since the news and has been consolidating around $2.50 since the 150% increase. The stock is performing well with strong technicals and fundamentals. We believe in waiting until a strong definitive signal is clear until a decision is made in regards to the future movement of this stock. It’s consolidating and looks like it could still run but until it breaks out of the consolidation trend, trade carefully with stop orders.

read more